In a recent study, Serrati et al. demonstrated that the presence of circulating PD1+ EVs drives resistance to anti-PD1 therapy, and performed a multivariate analysis to show that high level of PD1+ EVs, from T cells and B cells, and high level of PD-L1+ EVs from melanoma cells are both able to predict the response to immunotherapy treatment independently [124]. This evidence concerns the gene RPL17 and melanoma.